The role of corticoids in the management of advanced prostate cancer
González-Del-Alba Baamonde, A.án.; Sevillano Fernández, E.
Archivos Espanoles de Urologia 71(3): 281-287
2018
ISSN/ISBN: 0004-0614 PMID: 29633949 Document Number: 695713
Prostate cancer is the most frequent malignant tumor in males in developed countries and represents the second cause of cancer death. Over the last years, the number of treatments available for patients with advanced prostate cancer has improved significantly, achieving better disease control and notably better overall survival (1). Corticosteroids have been extensively used in the treatment of castration resistant prostate cancer due to their palliative benefits on symptoms secondary to their potent anti-inflammatory activity and their demonstrated antitumor activity. At present time, we have a wide therapeutic arsenal for patients with metastatic prostate cancer and concomitant medication with corticosteroids may counteract adverse events of the main validated therapies. Nevertheless, long term exposition to corticosteroid treatment required by prostate cancer patients may have negative implications in terms of development of potential adverse events and, in certain cases, even facilitating disease progression.